Intrust Bank NA Has $626,000 Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Intrust Bank NA cut its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 9.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,497 shares of the biotechnology company’s stock after selling 3,841 shares during the quarter. Intrust Bank NA’s holdings in ADMA Biologics were worth $626,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ADMA. Pictet Asset Management Holding SA boosted its holdings in ADMA Biologics by 10.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 30,885 shares of the biotechnology company’s stock valued at $530,000 after acquiring an additional 2,928 shares during the last quarter. New Age Alpha Advisors LLC bought a new stake in shares of ADMA Biologics in the 4th quarter valued at $221,000. Norges Bank acquired a new stake in shares of ADMA Biologics during the fourth quarter worth $2,047,000. Amica Mutual Insurance Co. bought a new position in ADMA Biologics during the fourth quarter worth $183,000. Finally, JPMorgan Chase & Co. lifted its holdings in ADMA Biologics by 272.5% in the fourth quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company’s stock valued at $13,159,000 after buying an additional 561,310 shares during the period. Institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Stock Down 0.1 %

ADMA Biologics stock opened at $20.26 on Friday. The company has a market capitalization of $4.79 billion, a PE ratio of 72.36 and a beta of 0.60. ADMA Biologics, Inc. has a 12-month low of $5.90 and a 12-month high of $23.64. The firm’s fifty day moving average is $17.13 and its 200 day moving average is $18.15. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.